Frequently Asked Questions
The market is segmented based on , By Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others), Product (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents), Therapy (On-Demand and Prophylaxis), Treatment (Replacement Therapy, ITI Therapy, and Gene Therapy) Industry Trends and Forecast to 2030.
.
The Global Hemophilia Treatment Market size was valued at USD 15197.80 USD Million in 2022.
The Global Hemophilia Treatment Market is projected to grow at a CAGR of 6.3% during the forecast period of 2023 to 2030.
The major players operating in the market include Baxter, Octapharma, CSL Limited, Grifols S.A., Bayer AG, Pfizer , Sanofi, Ferring B.V., BioMarin, Sangamo Therapeutics, Novo Nordisk A/S, Shire, Kedrion S.p.A, F.Hoffmann La Roche Ltd, Swedish Orphan Biovitrum AB.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia- Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, rest of Middle East & Africa.
